Charles Schwab Investment Management Inc. Acquires 6,927 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Charles Schwab Investment Management Inc. increased its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 472,547 shares of the biopharmaceutical company’s stock after acquiring an additional 6,927 shares during the period. Charles Schwab Investment Management Inc. owned about 0.83% of Agios Pharmaceuticals worth $15,528,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of AGIO. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. bought a new position in Agios Pharmaceuticals in the 4th quarter valued at $53,000. KBC Group NV boosted its position in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 611 shares during the last quarter. Quest Partners LLC boosted its position in Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the 3rd quarter valued at $146,000.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.93% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

AGIO has been the topic of a number of recent research reports. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, Scotiabank raised their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Trading Up 3.3 %

Shares of Agios Pharmaceuticals stock opened at $32.71 on Friday. The company has a market capitalization of $1.87 billion, a PE ratio of 2.88 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 12 month low of $27.14 and a 12 month high of $62.58. The stock’s fifty day simple moving average is $33.44 and its 200 day simple moving average is $41.43.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.